Cover Image

Immunogenicity assessment of elder hepatocellular carcinoma patients after inactivated whole-virion SARS-CoV-2 vaccination

Background Research on immunogenicity after 3rd SARS-CoV-2 vaccine in elder hepatocellular carcinoma (HCC) was limited. This study aimed to investigate the efficacy and influencing factors of inactivated SARS-CoV-2 vaccine in elder HCC. Research design and methods We assessed total antibodies, anti-...

Full description

Saved in:
Bibliographic Details
Main Authors: Ruyun Gao (Author), Cuiling Zheng (Author), Mengwei Yang (Author), Liyuan Dai (Author), Chen Chen (Author), Jiarui Yao (Author), Zhishang Zhang (Author), Le Tang (Author), Yuankai Shi (Author), Xiaohong Han (Author)
Format: Book
Published: Taylor & Francis Group, 2023-12-01T00:00:00Z.
Subjects:
article
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Research on immunogenicity after 3rd SARS-CoV-2 vaccine in elder hepatocellular carcinoma (HCC) was limited. This study aimed to investigate the efficacy and influencing factors of inactivated SARS-CoV-2 vaccine in elder HCC. Research design and methods We assessed total antibodies, anti-RBD IgG, and neutralizing antibodies (NAb) toward SARS-CoV-2 wild type (WT) as well as BA.4/5 in 304 uninfected HCC, 147 matched healthy control (HC), and 53 SARS-CoV-2 infected HCC, all aged over 60 years. The levels of antibodies were compared in the period 7-90, 91-180, and >180 days after 2nd or 3rd vaccination, respectively. Results HCC had lower seropositivity than HC after 2nd dose (total antibodies, 64%vs.92%,P < 0.0001; anti-RBD IgG, 50%vs.77%,P < 0.0001). But 3rd dose can efficaciously close the gap (total antibodies, 96%vs.100%,P = 0.1212; anti-RBD IgG: 87%vs.87%,P > 0.9999). Booster effect of 3rd dose can persist >180 days in HCC (2ndvs.3rd: total antibodies, 0.60vs.3.20,P < 0.0001; anti-RBD IgG, 13.86vs.68.85,P < 0.0001; WT NAb, 11.70vs.22.47,P < 0.0001). Vaccinated HCC had more evident humoral responses than unvaccinated ones after infection (total antibodies: 3.85vs.3.20,P < 0.0001; anti-RBD IgG: 910.92vs.68.85,P < 0.0001; WT NAb: 96.09vs.22.47,P < 0.0001; BA.4/5 NAb: 86.53vs.5.59,P < 0.0001). Conclusions Our findings highlight the booster effect and protective role of 3rd dose. Our results could provide a theoretical foundation for informing decisions regarding SARS-CoV-2 vaccination in elder HCC.
Item Description:1476-0584
1744-8395
10.1080/14760584.2023.2274484

Similar Items